Tirzepatide pros and cons: what the trial data really shows

Last updated 2026-07-30

What is tirzepatide and how does it work

Tirzepatide is a once-weekly injectable that activates two gut hormone receptors, GIP and GLP-1, instead of just one. That dual action is what separates it from older GLP-1-only drugs like semaglutide (Ozempic, Wegovy). Eli Lilly sells it under two brand names for two FDA-approved uses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition ^[1][2]. Same molecule, same doses, different label and different box. Compounded tirzepatide is a separate category. It's made by compounding pharmacies, not Lilly, and it is not FDA-approved, meaning it hasn't gone through the agency's efficacy and manufacturing review process. The FDA removed tirzepatide from its drug shortage list in December 2024, which narrowed the legal basis many compounders had relied on ^[3]. If you're comparing pros and cons of "tirzepatide" broadly, know which version you're actually talking about, because the evidence base below is for the branded, FDA-approved drug studied in trials. For a broader look at how people describe their actual experience on the drug, see tirzepatide reviews.

How well does tirzepatide work for weight loss

In the SURMOUNT-1 trial, adults with obesity (without diabetes) lost an average of 15.0% of body weight on the 5 mg dose, 19.5% on 10 mg, and 20.9% on 15 mg over 72 weeks, compared to 3.1% on placebo ^[4]. That's a mean. Individual results varied widely, and about 57% of people on the highest dose lost 20% or more of their body weight, per the same trial's published results. SURMOUNT-4 looked at what happens if you stop. People who took tirzepatide for 36 weeks and then switched to placebo regained a substantial share of the weight they'd lost, while those who stayed on the drug continued to lose more ^[5]. That single result answers the most common follow-up question: no, the weight loss doesn't appear to stick without continued treatment for most people. For context on how fast results show up and how they compare across the dose range, see tirzepatide results timeline and tirzepatide before and after data. | Trial | Population | Duration | Result |

How well does tirzepatide work for type 2 diabetes

The SURPASS program is the trial series that got Mounjaro approved. Across five head-to-head and placebo trials, tirzepatide lowered A1C between roughly 1.9 and 2.6 percentage points depending on dose and comparator ^[7][8]. SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in people with type 2 diabetes. Tirzepatide at all three doses (5, 10, 15 mg) beat semaglutide on both A1C reduction and weight loss over 40 weeks, with the 15 mg dose producing an A1C drop of 2.58% versus 1.86% for semaglutide ^[7]. That's one of the few large trials pitting a dual agonist directly against a single GLP-1 agonist, and it's the data point most often cited to argue tirzepatide is "stronger." A meaningful share of participants in SURPASS trials reached an A1C under 5.7%, technically in the non-diabetic range, without needing rescue medication. That's a genuinely strong result by the standards of modern diabetes drug trials, and it's the strongest argument in the "pro" column for this drug.

What are the real side effects of tirzepatide

Gastrointestinal side effects are the headline con, and they're common, not rare. Across SURMOUNT-1, nausea occurred in about 24-33% of tirzepatide-treated participants depending on dose, diarrhea in about 17-23%, vomiting in about 8-13%, and constipation in a similar range ^[4]. Most were described as mild to moderate and clustered around dose increases. These effects usually ease over the first several weeks as your body adjusts, but they're the number one reason people discontinue treatment. If you're starting soon, tirzepatide first month what to expect walks through the timeline in more detail. Less common but more serious: acute pancreatitis has been reported in clinical trials and postmarketing surveillance, gallbladder disease (including gallstones) shows up at a higher rate than placebo in trial data, and there's a hypoglycemia risk when tirzepatide is combined with insulin or sulfonylureas ^[1][2]. Injection site reactions are common but minor. The FDA label carries a boxed warning, the agency's strongest warning category, about thyroid C-cell tumors observed in rodent studies. It states tirzepatide is "contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" ^[1][2]. It isn't confirmed that this happens in humans, but the signal in rodents was strong enough that the FDA required the warning and the contraindication rather than just a caution.

Who should not take tirzepatide

Beyond the MTC/MEN2 contraindication, tirzepatide isn't recommended for people with a history of pancreatitis, severe gastrointestinal disease (it slows gastric emptying, which can worsen conditions like gastroparesis), or a known hypersensitivity to the drug or its components ^[1][2]. Pregnancy is another clear no. Animal studies showed fetal harm, and the labels advise discontinuing tirzepatide at least one month before a planned pregnancy ^[1][2]. There's no adequate human pregnancy safety data, so the honest answer for anyone trying to conceive is: stop it well in advance and talk to your prescriber about alternatives. People with type 1 diabetes were excluded from the major trials, and tirzepatide isn't approved for type 1 diabetes management. If you have significant kidney or liver impairment, gallbladder disease, or you're on multiple diabetes medications already, that's a conversation for your prescriber, not a self-directed decision, given the drug interaction and dose-titration complexity involved.

How does tirzepatide compare to semaglutide (Ozempic, Wegovy)

Head-to-head, tirzepatide edges out semaglutide on both weight loss and A1C reduction in the trials that have compared them directly. SURPASS-2 showed tirzepatide 15 mg beating semaglutide 1 mg on A1C (2.58% vs 1.86% reduction) and weight loss (12.4 kg vs 6.2 kg) over 40 weeks in people with type 2 diabetes ^[7]. There's no completed head-to-head SURMOUNT-vs-STEP trial for pure weight loss in non-diabetic populations, so most "tirzepatide vs semaglutide for weight loss" comparisons rely on cross-trial comparisons (SURMOUNT-1 vs STEP 1), which is a weaker form of evidence because trial populations and conditions differ. With that caveat, SURMOUNT-1's 20.9% mean weight loss at the top dose is higher than the roughly 14.9% seen in STEP 1 for semaglutide 2.4 mg over a similar duration. The tradeoff isn't just efficacy. Tirzepatide's dual mechanism means a somewhat different side effect intensity curve for some people, and the two drugs aren't interchangeable mid-treatment without a doctor managing the switch. Cost and insurance coverage often matter more in practice than the small efficacy gap, since both drugs are expensive and coverage varies by plan and diagnosis.

What does tirzepatide cost and is it covered by insurance

List price for Zepbound and Mounjaro runs over $1,000 per month without insurance, though actual out-of-pocket cost varies enormously by insurance plan, pharmacy, and whether a manufacturer savings card applies. Lilly has also sold single-dose vials of Zepbound directly through its LillyDirect self-pay pharmacy program at a lower list price than the auto-injector version, specifically for cash-pay patients. Medicare Part D does not cover Zepbound or Mounjaro for weight loss alone, though Medicare can cover Mounjaro when prescribed for type 2 diabetes, subject to the plan's formulary. Commercial insurance coverage for weight-loss use varies widely and often requires prior authorization showing a BMI threshold or a weight-related comorbidity. This cost reality is a genuine "con" that trial data alone doesn't capture: efficacy is only half the equation. Anyone deciding between drugs should also weigh whether their specific plan covers one and not the other, since that can matter more than the few percentage points separating tirzepatide from semaglutide in trials. For a fuller cost-benefit framing, see is tirzepatide worth it.

Do you have to take tirzepatide forever

For most people, yes, in the sense that stopping leads to weight regain. SURMOUNT-4's withdrawal data is the clearest evidence: participants who discontinued tirzepatide after an initial 36-week run-in regained a large share of lost weight over the following 52 weeks, while those who continued treatment kept losing ^[5]. This mirrors what's been shown with semaglutide (STEP 1 extension data showed similar regain after discontinuation) and fits the current medical understanding of obesity as a chronic condition requiring chronic management, not a course of treatment with a defined end date, similar to how blood pressure or cholesterol medication works for many patients. That's a real con for people hoping for a fixed-term fix, and a real consideration for the total cost calculation over years, not months. It's also why some clinicians frame the drug less like an antibiotic and more like a long-term maintenance medication.

What is the honest success rate for tirzepatide

"Success" depends on your bar. If success means losing at least 5% of body weight (the threshold the FDA and obesity medicine groups use to define clinically meaningful weight loss), the vast majority of trial participants got there. If the bar is 20%+ total body weight loss, roughly half of people on the highest dose hit that mark in SURMOUNT-1 ^[4]. Not everyone responds the same way. Individual variation in the trials was wide, and factors like starting weight, adherence to dose titration, diet quality during treatment, and how well someone tolerates the GI side effects all affect where a given person lands. A smaller share of participants are "non-responders" who see minimal benefit even at the top dose, though the exact percentage varies by trial and definition. See tirzepatide success rate for the fuller breakdown of response rates by dose and population.

Tirzepatide pros and cons at a glance

Here's the balance sheet, stripped of marketing language on either side. Pros: Strongest average weight loss (up to 20.9% at 15 mg) and A1C reduction (up to 2.58%) of any FDA-approved drug in its class in head-to-head data ^[4][7]. Once-weekly dosing. Outperformed semaglutide directly in SURPASS-2. FDA-approved for two distinct, well-studied indications (Mounjaro for T2D, Zepbound for weight) with a large trial base behind both labels ^[1][2]. Cons: Common GI side effects (nausea, diarrhea, vomiting, constipation) affecting a large minority to majority of users depending on dose ^[4]. Boxed warning for thyroid C-cell tumor risk based on rodent studies, with a hard contraindication for personal or family MTC/MEN2 history ^[1][2]. Pancreatitis and gallbladder disease signals. Weight regain after stopping, per SURMOUNT-4 ^[5]. High cost, inconsistent insurance coverage, and no long-term (multi-year) safety data yet since the drug is relatively new to market. Not studied in type 1 diabetes, and contraindicated or cautioned against in several specific patient groups. None of that makes tirzepatide a bad drug. It makes it a serious medication with real tradeoffs, which is exactly what the trial data says, not a magic shot with no downside.

How should you decide if tirzepatide is right for you

Start with your diagnosis and your risk factors, not the marketing. If you have type 2 diabetes and haven't hit your A1C goal, or you meet the BMI/comorbidity criteria for chronic weight management, tirzepatide has real trial evidence behind it for you specifically. If you don't have a personal or family history of medullary thyroid cancer or MEN2, and you don't have severe GI disease or pancreatitis history, you're in the population the trials actually studied. Talk through the tradeoffs concretely with a prescriber: how you'll handle nausea in the first few weeks, what the dose titration schedule looks like, how much this will cost monthly with your specific insurance, and what your plan is if you eventually stop (because most people either keep taking it long-term or lose ground, per SURMOUNT-4). If you're ready to move forward, get it through a provider-reviewed process rather than an unverified source. Tirz Rx reviews options that connect you with a licensed prescriber and a fulfilling pharmacy partner, so the dose, the monitoring, and the sourcing are all handled by people accountable for it, not a random online seller.

Frequently asked questions

What are the biggest downsides of tirzepatide?

The most common downside is GI side effects (nausea, diarrhea, vomiting, constipation), affecting a large share of users especially during dose increases. Less common but more serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors seen in rodent studies. Cost (often $1,000+/month without coverage) and the likelihood of weight regain after stopping round out the real cons.

Does tirzepatide cause cancer?

There's no confirmed evidence tirzepatide causes cancer in humans. The boxed warning is based on thyroid C-cell tumors seen in rodent studies, and the FDA required a contraindication for people with personal or family history of medullary thyroid carcinoma or MEN2 syndrome as a precaution ^[1][2]. Human long-term cancer data doesn't yet exist because the drug is still relatively new.

Is tirzepatide better than semaglutide?

In the one major head-to-head trial (SURPASS-2), tirzepatide outperformed semaglutide 1 mg on both A1C reduction (2.58% vs 1.86%) and weight loss over 40 weeks in people with type 2 diabetes ^[7]. There's no completed head-to-head weight-loss-only trial, so cross-trial comparisons suggest an edge for tirzepatide but aren't as reliable as direct comparison data.

How much weight can you realistically lose on tirzepatide?

In SURMOUNT-1, average weight loss ranged from 15.0% of body weight at the 5 mg dose to 20.9% at 15 mg over 72 weeks, versus 3.1% on placebo ^[4]. Individual results vary widely; roughly half of people on the top dose lost 20% or more, but some lose considerably less.

Do you gain the weight back after stopping tirzepatide?

Most people regain a substantial portion of lost weight after stopping. SURMOUNT-4 showed participants who switched to placebo after 36 weeks on tirzepatide regained significant weight over the following year, while those who stayed on treatment kept losing ^[5]. This is consistent with obesity being treated as a chronic condition.

Who should not take tirzepatide?

People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are contraindicated ^[1][2]. Caution or avoidance is also warranted for those with a history of pancreatitis, severe GI disease, pregnancy or plans to conceive soon, and type 1 diabetes, since trials didn't study that population.

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide, made by the same manufacturer (Eli Lilly), in the same dose range, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition ^[1][2].

Is compounded tirzepatide as safe as the brand name?

Compounded tirzepatide isn't FDA-approved, meaning it hasn't gone through the agency's efficacy and manufacturing review. The FDA removed tirzepatide from its drug shortage list in December 2024, narrowing the legal basis compounders had used ^[3]. Quality and dosing accuracy can vary by compounding pharmacy in ways the branded product's trials don't capture.

What are the most common side effects of tirzepatide in trials?

In SURMOUNT-1, nausea occurred in roughly 24-33% of participants depending on dose, diarrhea in about 17-23%, vomiting in 8-13%, and constipation at similar rates ^[4]. Most were mild to moderate and tended to occur around dose increases, easing over time for many users.

Does insurance cover tirzepatide for weight loss?

Coverage varies widely by plan. Medicare Part D doesn't cover Zepbound for weight loss, though it can cover Mounjaro for type 2 diabetes depending on the plan's formulary. Commercial insurance often requires prior authorization tied to BMI or a weight-related comorbidity, and many plans still exclude weight-loss drugs entirely.

How long does it take to see results on tirzepatide?

Trial data shows measurable weight loss and A1C improvement within the first several weeks, with effects building through dose titration over roughly 20-24 weeks and continuing through 72 weeks in SURMOUNT-1 ^[4]. Most people notice appetite changes within the first two to four weeks.

Can tirzepatide cause gallbladder problems?

Yes. Gallbladder disease, including gallstones, occurred at a higher rate in tirzepatide trial groups than in placebo groups across the SURMOUNT and SURPASS programs ^[1][2]. Rapid weight loss itself is also an independent risk factor for gallstones, so this risk isn't unique to the drug's mechanism alone.

Sources

1. FDA, Mounjaro (tirzepatide) prescribing information: Boxed warning for thyroid C-cell tumors, contraindication for personal/family MTC or MEN2 history, GI and pancreatitis warnings, pregnancy guidance
2. FDA, Zepbound (tirzepatide) prescribing information: Zepbound approval for chronic weight management, boxed warning, contraindications, side effect profile
3. FDA, Tirzepatide shortage resolution notice: FDA removed tirzepatide from the drug shortage list in December 2024
4. Jastreboff et al., NEJM, SURMOUNT-1 trial: Weight loss of 15.0-20.9% across tirzepatide doses vs 3.1% placebo over 72 weeks; side effect rates
5. ClinicalTrials.gov, SURMOUNT-4 (NCT04660643): SURMOUNT-4 trial design and withdrawal/continuation weight regain comparison
6. Le Roux et al., The Lancet, SURMOUNT-2 trial: Weight loss up to 15.7% in people with obesity and type 2 diabetes over 72 weeks
7. Frias et al., NEJM, SURPASS-2 trial: Tirzepatide vs semaglutide 1 mg: A1C reduction of 2.58% vs 1.86%, weight loss 12.4 kg vs 6.2 kg over 40 weeks
8. ClinicalTrials.gov, SURPASS-1 through SURPASS-5 program listing: SURPASS clinical trial program design supporting Mounjaro's type 2 diabetes approval